• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Microbiological reviews >Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease
【24h】

Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

机译：H因子结合蛋白在脑膜炎奈瑟氏菌毒力中的作用及其作为广泛预防脑膜炎球菌疾病的疫苗候选者的潜力

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans and can cause devastating invasive disease. Although capsular polysaccharide-based vaccines against serogroups A, C, Y, and W135 are widely available, the pathway to a broadly protective vaccine against serogroup B has been more complex. The last 11 years has seen the discovery and development of the N. meningitidis serogroup B (MnB) outer membrane protein factor H binding protein (fHBP) as a vaccine component. Since the initial discovery of fHBP, a tremendous amount of work has accumulated on the diversity, structure, and regulation of this important protein. fHBP has proved to be a virulence factor for N. meningitidis and a target for functional bactericidal antibodies. fHBP is critical for survival of meningococci in the human host, as it is responsible for the primary interaction with human factor H (fH). Binding of hfH by the meningococcus serves to downregulate the host alternative complement pathway and helps the organism evade host innate immunity. Preclinical studies have shown that an fHBP-based vaccine can elicit serum bactericidal antibodies capable of killing MnB, and the vaccine has shown very encouraging results in human clinical trials. This report reviews our current knowledge of fHBP. In particular, we discuss the recent advances in our understanding of fHBP, its importance to N. meningitidis , and its potential role as a vaccine for preventing MnB disease.
机译：脑膜炎奈瑟氏球菌是革兰氏阴性微生物，仅存在于人类中，可导致毁灭性的侵袭性疾病。尽管针对血清群A，C，Y和W135的基于荚膜多糖的疫苗已广泛可用，但针对血清群B的广泛保护性疫苗的途径却更为复杂。在最近的11年中，脑膜炎双球菌血清群B（MnB）外膜蛋白因子H结合蛋白（fHBP）作为疫苗成分的发现和发展。自从首次发现fHBP以来，在这一重要蛋白质的多样性，结构和调控方面积累了大量工作。 fHBP已被证明是脑膜炎奈瑟氏球菌的致病因子，也是功能性杀菌抗体的靶标。 fHBP对于脑膜炎球菌在人类宿主中的存活至关重要，因为它与人因子H（fH）发生主要相互作用。脑膜炎双球菌与hfH的结合可下调宿主的替代补体途径，并有助于生物体逃避宿主的先天免疫力。临床前研究表明，基于fHBP的疫苗可以引发能够杀死MnB的血清杀菌抗体，该疫苗在人体临床试验中显示出令人鼓舞的结果。本报告回顾了我们目前对fHBP的了解。特别是，我们讨论了对fHBP的了解，其对脑膜炎奈瑟氏菌的重要性及其作为预防MnB疾病的疫苗的潜在作用的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号